Expanding antigen-specific regulatory networks to treat autoimmunity

Nature

Volumn 530, Issue 7591, 2016, Pages 434-440

  Clemente Casares, Xavier ^a   Blanco, Jesus ^b,c   Ambalavanan, Poornima ^a   Yamanouchi, Jun ^a   Singha, Santiswarup ^a   Fandos, Cesar ^b   Tsai, Sue ^a   Wang, Jinguo ^a   Garabatos, Nahir ^d   Izquierdo, Cristina ^d   Agrawal, Smriti ^e   Keough, Michael B ^e   Yong, V Wee ^e   James, Eddie ^f   Moore, Anna ^g   Yang, Yang ^a   Stratmann, Thomas ^d   Serra, Pau ^b   Santamaria, Pere ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e UNIVERSITY OF CALGARY   (Canada)

^f BENAROYA RESEARCH INSTITUTE   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; INTERLEUKIN 3; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NANOPARTICLE; TRANSFORMING GROWTH FACTOR BETA; AUTOANTIGEN; CD11 ANTIGEN; CYTOKINE; HLA ANTIGEN CLASS 2;

ANTIGEN; CELLS AND CELL COMPONENTS; DISEASE TREATMENT; HISTOPATHOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; BIOLOGICAL ACTIVITY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; GENETIC BACKGROUND; LYMPHOCYTE DIFFERENTIATION; MOTOR PERFORMANCE; MOUSE; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SYSTEMIC THERAPY; T LYMPHOCYTE; THERAPY EFFECT; ANIMAL; C57BL MOUSE; CELL DIFFERENTIATION; CHEMISTRY; CYTOLOGY; GENETICS; HUMAN; IMMUNOLOGY; NONOBESE DIABETIC MOUSE; PREVALENCE; SOLUBILITY; TRANSGENIC MOUSE;

MUS;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD11; AUTOANTIGENS; AUTOIMMUNITY; B-LYMPHOCYTES; CELL DIFFERENTIATION; CYTOKINES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, TRANSGENIC; NANOMEDICINE; NANOPARTICLES; ORGAN SPECIFICITY; PREVALENCE; SOLUBILITY; T-LYMPHOCYTES, REGULATORY;

EID: 84959450362     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature16962     Document Type: Article

References (31)

1. Santamaria, P. The long and winding road to understanding and conquering type 1 diabetes. Immunity 32, 437-445 (2010).
2. Babbe, H. et al. Clonal expansions of CD8+ T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 192, 393-404 (2000).
3. Firestein, G. S. Evolving concepts of rheumatoid arthritis. Nature 423, 356-361 (2003).
4. Sakaguchi, S. et al. Foxp3+CD25+CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 212, 8-27 (2006).
5. Zhou, X. et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nature Immunol. 10, 1000-1007 (2009).
6. Komatsu, N. et al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nature Med. 20, 62-68 (2014).
7. Bailey-Bucktrout, S. L. et al. Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity 39, 949-962 (2013).
8. Gagliani, N. et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nature Med. 19, 739-746 (2013).
9. McLarnon, A. IBD: regulatory T-cell therapy is a safe and well-tolerated potential approach for treating refractory Crohn's disease. Nature Rev. Gastroenterol. Hepatol. 9, 559 (2012).
10. Desreumaux, P. et al. Safety and Efficacy of Antigen-Specific Regulatory T-Cell Therapy for Patients With Refractory Crohn's Disease. Gastroenterology 143, 1207-1217 (2012).
11. Roncarolo, M. G., Gregori, S., Lucarelli, B., Ciceri, F. & Bacchetta, R. Clinical tolerance in allogeneic hematopoietic stem cell transplantation. Immunol. Rev. 241, 145-163 (2011).
12. Tsai, S. et al. Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity 32, 568-580 (2010).
13. Stratmann, T. et al. Susceptible MHC alleles, not background genes, select an autoimmune T cell reactivity. J. Clin. Invest. 112, 902-914 (2003).
14. Kamanaka, M. et al. Expression of interleukin-10 in intestinal lymphocytes detected by an interleukin-10 reporter knockin tiger mouse. Immunity 25, 941-952 (2006).
15. Mukherjee, R., Wagar, D., Stephens, T., Le-Chan, E. & Singh, B. Identification of CD4+ T cell-specific epitopes of islet-specific glucose-6-phosphatase catalytic subunit-related protein: a novel β cell autoantigen in type 1 diabetes. J. Immunol. 174, 5306-5315 (2005).
16. Burton, B. R. et al. Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy. Nature Commun. 5, 4741-4747 (2014).
17. Getts, D. R. et al. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nature Biotechnol. 30, 1217-1224 (2012).
18. Pot, C. et al. Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. J. Immunol. 183, 797-801 (2009).
19. Spensieri, F. et al. Human circulating influenza-CD4+ICOS1+IL-21+ T cells expand after vaccination, exert helper function, and predict antibody responses. Proc. Natl Acad. Sci. USA 110, 14330-14335 (2013).
20. Hale, J. S. et al. Distinct memory CD4+ T cells with commitment to T follicular helper- and T helper 1-cell lineages are generated after acute viral infection. Immunity 38, 805-817 (2013).
21. Sato, K. et al. Marked induction of c-Maf protein during Th17 cell differentiation and its implication in memory Th cell development. J. Biol. Chem. 286, 14963-14971 (2011).
22. Saraiva, M. et al. Interleukin-10 production by Th1 cells requires interleukin- 12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity 31, 209-219 (2009).
23. Verdaguer, J. et al. Spontaneous autoimmune diabetes in monoclonal T cell nonobese diabetic mice. J. Exp. Med. 186, 1663-1676 (1997).
24. Wang, J. et al. In situ recognition of autoantigen as an essential gatekeeper in autoimmune CD8+ T cell inflammation. Proc. Natl Acad. Sci. USA 107, 9317-9322 (2010).
25. Yang, J. et al. Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjects. J. Immunol. 176, 2781-2789 (2006).
26. Holst, J. et al. Generation of T-cell receptor retrogenic mice. Nature Protocols 1, 406-417 (2006).
27. Reijonen, H. et al. Detection of GAD65-specific T cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects. Diabetes 51, 1375-1382 (2002).
28. Yang, J. et al. CD4+ T cells from type 1 diabetic and healthy subjects exhibit different thresholds of activation to a naturally processed proinsulin epitope. J. Autoimmun. 31, 30-41 (2008).
29. Moore, A., Grimm, J., Han, B. & Santamaria, P. Tracking the recruitment of diabetogenic CD8+ T cells to the pancreas in real time. Diabetes 53, 1459-1466 (2004).
30. Giuliani, F. et al. Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J. Neuroimmunol. 158, 213-221 (2005).
31. Leavenworth, J. W., Tang, X., Kim, H. J., Wang, X. & Cantor, H. Amelioration of arthritis through mobilization of peptide-specific CD8+ regulatory T cells. J. Clin. Invest. 123, 1382-1389 (2013).